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Abstract
Background: Rett Syndrome (RTT) is an Autism Spectrum Disorder and the leading cause of mental retardation in females.
RTT is caused by mutations in the Methyl CpG-Binding Protein-2 (MECP2) gene and has no treatment. Our objective is to
develop viral vectors for MECP2 gene transfer into Neural Stem Cells (NSC) and neurons suitable for gene therapy of Rett
Syndrome.
Methodology/Principal Findings: We generated self-inactivating (SIN) retroviral vectors with the ubiquitous EF1a promoter
avoiding known silencer elements to escape stem-cell-specific viral silencing. High efficiency NSC infection resulted in long-
term EGFP expression in transduced NSC and after differentiation into neurons. Infection with Myc-tagged MECP2-isoform-
specific (E1 and E2) vectors directed MeCP2 to heterochromatin of transduced NSC and neurons. In contrast, vectors with an
internal mouse Mecp2 promoter (MeP) directed restricted expression only in neurons and glia and not NSC, recapitulating
the endogenous expression pattern required to avoid detrimental consequences of MECP2 ectopic expression. In
differentiated NSC from adult heterozygous Mecp2
tm1.1Bird+/2 female mice, 48% of neurons expressed endogenous MeCP2
due to random inactivation of the X-linked Mecp2 gene. Retroviral MECP2 transduction with EF1a and MeP vectors rescued
expression in 95–100% of neurons resulting in increased dendrite branching function in vitro. Insulated MECP2 isoform-
specific lentiviral vectors show long-term expression in NSC and their differentiated neuronal progeny, and directly infect
dissociated murine cortical neurons with high efficiency.
Conclusions/Significance: MeP vectors recapitulate the endogenous expression pattern of MeCP2 in neurons and glia. They
have utility to study MeCP2 isoform-specific functions in vitro, and are effective gene therapy vectors for rescuing dendritic
maturation of neurons in an ex vivo model of RTT.
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Introduction
Rett Syndrome (RTT) is an X-linked progressive neurological
disorderaffecting1 inevery 10,000female births that leadstosevere
mental retardation. RTT patients develop normally up to 6–18
months of age, when they start to develop symptoms including loss
of speech and purposeful hand movements, seizures, respiratory
abnormalities, anxiety and autism [1]. RTT is caused by mutations
in the methyl-CpG binding protein-2 (MECP2) gene. MeCP2 has
two NLS (Nuclear Localization Signals) and three principal
domains; the Methyl DNA Binding Domain (MBD), the Tran-
scriptional Repression Domain (TRD) and a C-terminal domain.
Implicated as both an activator and a repressor [2,3], MeCP2 binds
via its MBD to methylated CpG dinucleotides adjacent to A/T
sequences[4]and recruitsHDAC1/2 (Histone Deacetylase1 and 2)
and transcriptional regulator Sin3A [5,6]. The TRD can also
function as a nonspecific DNA binding domain [7]. To fully assert
its gene repression activity on target genes, MeCP2 interacts with
the Brahma component of SWI/SNF chromatin remodeling
complex [8], HP1 isoforms (Cbx1, 3, 5) [9], and DNMT1 (DNA
methyltransferase 1) [10]. In addition, interactions with RNA-
binding protein YB1 (Y box-binding protein 1) [11] forms
complexes that modulate RNA splicing patterns. MECP2 mutations
have different impacts in protein function depending on where the
mutation lies. For example, distinct mutations within the MBD
result in structural protein changes that alter protein folding and
DNA interaction abilities of MeCP2 [7,12]. Although the function
of MeCP2 through these interactions is not clearly established, they
highlight its multiple roles in gene repression, chromatin conden-
sation/remodeling and RNA splicing.
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6810MeCP2 isoforms E1 and E2 are generated by alternative
splicing of exon 2 to produce proteins with differing N termini
[13]. MECP2 transcripts are expressed almost ubiquitously with
higher expression of the E1 isoform in the brain [14], but no
MeCP2 expression is detected in Neural Stem Cells (NSC) grown
as neurospheres. Although MeCP2 is widely expressed, RTT
symptoms are primarily neuronal and confirmed MeCP2 targets
in neurons include BDNF (Brain Derived Neurotrophic Factor)
[15–17] and DLX5 (Distal-less homeobox 5) [18]. It was recently
reported that MeCP2 is expressed at low levels in glia. In
particular GFAP+ astrocytes support normal neuronal growth, but
MeCP2-deficient astrocytes have a non-cell autonomous effect on
dendritic morphology of cocultured neurons exerted through
aberrant secretion of a soluble factor [19]. Thus it is important to
maintain MeCP2 expression in both neurons and glia.
Currently, there is no effective treatment for Rett Syndrome.
However, it has been shown that reactivation of the Mecp2 gene
after the onset of disease in RTT mouse models rescues the
phenotype [20,21]. This finding raises gene therapy prospects by
delivering MECP2 to the affected neurons and glia or their
progenitors. Retroviral and lentiviral vectors integrate into the
genome and provide stable gene transfer. However, these vectors
are often subject to transcriptional silencing in stem cells, and
when silent are bound by MeCP2 [22–26] and other repressor
complexes. Thus these vectors may also be silenced in NSC,
consequently limiting their gene transfer application for gene
therapy of neurological diseases. Therefore, it is important to study
vector expression in stem cell systems tailored for gene transfer.
Delivery of the MECP2 gene by direct viral infection, or by
transplantation of engineered NSC into specific regions of the
brain to migrate and differentiate into neurons and glia, may
ameliorate Rett Syndrome symptoms. However, the vectors must
be designed to direct long-term expression in the correct cell types.
We have designed MECP2 isoform-specific retroviral vectors
with ubiquitous (EF1a) or endogenous Mecp2 (MeP) internal
promoters. We demonstrate long-term expression of the EF1a
vectors after transduction of embryonic and adult murine NSC
and differentiation into neurons. The MeP vector recapitulates
endogenous MeCP2 expression in neurons and glia but not NSC,
and thus is well suited for gene therapy. Retroviral gene transfer of
the E1 isoform into Mecp2
tm1.1Bird+/2 NSC directed expression in
95% of the differentiated cells, and demonstrates a functional role
for MeCP2-E1 in regulating dendrite length and branching during
morphological maturation of neurons in vitro. Equivalent lentiviral
EF1a vectors express long-term in NSC and their progeny
neurons, while lentiviral MeP vectors express MECP2 isoforms
after direct gene transfer into cortical neurons and glia. These
MECP2 vectors will facilitate functional studies on the isoforms
and ultimately have applications for RTT gene therapy.
Results
Efficient transduction and long-term expression of
MECP2 retroviral vectors in NSC
To create retroviral vectors for gene delivery into NSC, we
combined the self-inactivating (SIN) HSC1 retroviral backbone
with a strong ubiquitous 1.3 kb EF1a promoter [27] suitable for
high expression in stem cells. SIN vectors carry a deleted LTR
(Long Terminal Repeat) promoter that results in transcriptional
initiation exclusively from the internal promoter. To assess
expression of control Retro-EF1a-EGFP vector (Figure 1A),
isolated NSC from embryonic (E14) mouse forebrain were grown
in the presence of rhEGF and bFGF, and dissociated cells were
infected. EGFP expression from transduced NSC was detectable
within 48 h of infection by live imaging (Figure 1B) and persisted
during neurosphere formation in 60% of cells as detected by flow
cytometry (Figure 1C).
To avoid stem cell-specific silencing [27,28], we did not include
EGFP in the MECP2 vectors. EGFP cDNA contains 60 CpG
dinucleotides within the coding sequence and could be subject to
silencing via DNA methylation that could become a target for
MeCP2 [27]. We therefore generated Retro-EF1a-MECP2-E1 or -
E2 vectors using Myc-tagged cDNAs to distinguish them from the
endogenous protein (Figure 2A). Immunofluorescence (IF) staining
of dissociated NSC with anti Myc-tag and anti MeCP2 antibodies
showed that .70% to .80% of cells are infected with Retro-
EF1a-E1 or Retro-EF1a-E2 respectively (Figure 2B). Confocal
single cell images showed colocalization of Myc-tag and MeCP2
signals at DAPI-rich heterochromatic regions of the nucleus
(Figure 2C). The specificity of MeCP2-myc staining is clear in
Figure 1. Efficient transduction of NSCs by a retroviral vector expressing EGFP. A) Schematic of the retroviral vector expressing EGFP
under the control of the EF1a promoter. SIN LTR: Self-inactivating Long Terminal Repeat. B) Primary neurospheres infected with Retro-EF1a-EGFP
expressed EGFP under fluorescence microscope. C) Flow cytometry analysis of infected primary neurospheres shows 60% EGFP positive cells.
doi:10.1371/journal.pone.0006810.g001
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PLoS ONE | www.plosone.org 2 August 2009 | Volume 4 | Issue 8 | e6810Figure 2. Efficient transduction of NSCs by retroviral vectors expressing MeCP2 isoforms. A) Schematic of the retroviral vectors
expressing human MeCP2 isoforms (E1 or E2) with Myc-tag under the control of the EF1a promoter. B) Ratio of Myc-tagged MeCP2 positive cells in
dissociated embryonic NSCs after retroviral infection. C) Confocal microscope images of the infected NSCs show punctate staining with colocalization
of Myc-tag and MeCP2 protein at DAPI-rich regions. D) Both E1 and E2 isoforms were detected in transduced NSCs (1
st sphere for E2 isoform, and 1
st,
3
rd,8
th, and 10
th spheres for E1 isoform) by Western blot (WB) using anti Myc-tag antibody.
doi:10.1371/journal.pone.0006810.g002
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molecular weight of MeCP2 in Western blots (WB) is between
70 kDa and 100 kDa, depending on the cell type, antibody used
and post-translational modifications. We detected both MeCP2
isoforms with the Myc-tag at 80–85 kDa in infected primary
transduced neurospheres by WB (Figure 2D). We conclude that
MECP2 isoform-specific retroviral vectors transduce embryonic
NSC with high efficiency directing MeCP2 correctly to hetero-
chromatic regions of the nucleus.
To examine long-term vector expression of the transduced
genes, we monitored EGFP expression over 10 neurosphere
passages by flow cytometry and did not detect any decrease in the
percentage of EGFP expressing cells. We also collected protein
extracts from Retro-EF1a-E1 infected NSC at the 3
rd,8
th and 10
th
neurosphere passages and by WB detected MeCP2-myc expres-
sion at all passages (Figure 2D). These results indicate that infected
NSC express transduced genes in long-term cultures, and high
levels of expression are obtained from the EF1a promoter.
Moreover, Retro-EF1a-EGFP and E1 in vitro transduced NSC
injected into WT brain tissue in culture resulted in EGFP
expressing cells within the brain slices (Figure S1) demonstrating
transduced gene delivery via NSC injection into the brain
microenvironment.
Mecp2 promoter recapitulates endogenous MeCP2
expression in neurons and in glia
MeCP2 overexpression in mice causes severe motor dysfunction
when expressed in a WT background, while neuronal-specific
transgene expression in Mecp2 mutant mice rescues the RTT
phenotype [29]. It is therefore critical to maintain restricted levels
of MeCP2 by employing endogenous regulatory elements. A
previously reported Mecp2 promoter [30], that we refer to as MeP,
was used to generate EGFP (control) and MECP2-E1 or -E2
retroviral vectors for regulated expression in neuronal tissue.
Retro-MeP-EGFP (Figure 3A) vector did not express EGFP in
transduced NSC as expected (Figure 3B, left). For potential RTT
gene therapy, MeCP2 must be expressed in affected neurons and
their supporting glial cells. We therefore differentiated transduced
NSC for 7 days in the presence of serum and withdrawal of rhEGF
and bFGF. EGFP expression from Retro-MeP-EGFP vector was
induced in the resulting cells (56%) as detected by flow cytometry
(Figure 3B, right) and IF (Figure 3C). WB of protein extracts from
transduced NSC confirmed that both isoforms express long-term
from the EF1a promoter, but expression from the MeP promoter
is negligible until NSC are induced to differentiate (data not
shown). To confirm the neuronal source of MeP directed EGFP in
differentiated NSC, we performed IF and found EGFP-expressing
neuronal (Figure 3C) and non-neuronal cells based on Tubulin III
(=bIII Tubulin, or also known as Tubb3) staining.
MeCP2 has been reported to be expressed in neurons and to a
lower level in glia [19,31,32], and the Mecp2 promoter is known to
be primarily neuronal in transgenic mice [30,33]. Based on the
Retro-MeP-EGFP expression pattern, we hypothesized that
Retro-MeP-MECP2-E1 and -E2 vectors (Figure 4A) may in fact
recapitulate low-level endogenous MeCP2 expression in non-
neuronal cells. We first investigated endogenous MeCP2 expres-
sion after in vitro differentiation of embryonic NSC. MeCP2 was
detectable at D7 but not at D0 in Tubulin III+ neurons and in
most differentiated cells (not shown). Further IF for GFAP, which
is expressed in astrocytes, revealed that MeCP2 is expressed in the
nuclei of glia differentiated from both embryonic and adult NSC
(not shown). To address whether in vivo differentiated GFAP+ glia
express MeCP2, we dissociated neurons and glia from the
forebrain of E18 mouse embryos. While neurons strongly
expressed nuclear MeCP2 colocalized with DAPI signals
(Figure 4B), lower expression in glia was also detected
(Figure 4B). We conclude that endogenous MeCP2 is expressed
in neurons and to lower levels in GFAP+ glia as reported [19]. As
expected, MeCP2-myc expression directed from the MeP
promoter vectors was also detected in differentiated Tubulin III+
neurons derived from transduced NSC (Figure 4C). We confirmed
expression in GFAP+ cells of transduced MeCP2 directed from
both EF1a and MeP promoters, demonstrating that the MeP
promoter is active in these cells (Figure 4D). Together, these data
clearly show MeCP2 expression in GFAP+ cells derived in vitro and
Figure 3. Regulated MeP promoter expresses EGFP in neurons
but not NSCs. A) Schematic of the retroviral vector expressing EGFP
under the control of MeCP2 (MeP) promoter. B) Flow cytometry analysis
shows that MeP promoter only expressed EGFP after 7 day
differentiation of NSCs into neurons, whereas control Retro-EF1a-EGFP
vector expressed in both undifferentiated and differentiated NSCs. C)
Immunofluorescence staining images show that Tubulin III positive
neurons express EGFP after differentiation of NSCs infected with Retro-
MeP-EGFP. Scale bars represent 50 mm.
doi:10.1371/journal.pone.0006810.g003
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PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6810Figure 4. MeP promoter is active in neurons and glia. A) Schematic of the retroviral vectors expressing human MeCP2 isoforms (E1 or E2) with
Myc-tag under the control of MeCP2 (MeP) promoter. B) Expression of endogenous MeCP2 protein in cortical neurons and glia isolated from E18
mouse brain. C) MeP promoter expressed MeCP2-E1 (top) or E2 (bottom) protein in Tubulin III positive neurons after 7 days differentiation of infected
NSCs. D) EF1a promoter and MeP promoter expressed MeCP2-E1 or E2 protein in GFAP positive glia after 7 days differentiation of infected NSCs. Scale
bars represent 50 mm.
doi:10.1371/journal.pone.0006810.g004
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expression pattern.
MECP2 retrovirus vector delivery into NSC of adult
Mecp2
tm1.1Bird+/2 female mice
As RTT is a postnatal neurological disorder, it is important to
confirm that retrovirus expression is maintained long-term in
transduced adult NSC. To study retrovirus vector expression in an
RTT model, one year old Mecp2
tm1.1Bird+/2 female mice showing
RTT symptoms (Figure S2A) were used to isolate NSC. The cells
were cultured for 20 neurosphere passages with no difficulty in
generating new neurospheres (Figure S2B). Transduction of these
cells with Retro-EF1a-EGFP resulted in EGFP expressing neuro-
spheres that continued to express EGFP for 10 passages (Figure 5,
green line) with comparable expression to primary spheres infected
at the 10
th passage (39.4% and 34.8% respectively, Figure 5, upper
right). Differentiation of these transduced NSC did not result in
EGFP silencing (data not shown). As expected, no significant
EGFP expression was detected in NSC transduced with Retro-
MeP-EGFP (Figure 5, blue line). Injection of Retro EF1a-EGFP
expressing transduced NSC into +/2 brain slices in culture
resulted in EGFP expressing cells that migrated and were
detectable by live imaging monitored up to 3 weeks (Figure 6).
Thus, RTT model NSC can be effectively transduced with
retroviral vectors that maintain reporter gene expression.
To examine retrovirus vector expression of MECP2, the isolated
+/2 NSC were transduced with Retro-EF1a-E1 and Retro-MeP-
E1. Robust expression was detected by WB from the ubiquitous
EF1a promoter and negligible expression from the MeP promoter
in the 1
st,2
nd and 3
rd passage (Figure 7A). Dissociated NSC
transduced with Retro-EF1a-E1 but not with Retro-MeP-E1
showed punctate Myc-tag and MeCP2 signals (Figure 7B)
confirming the WB data. To assess endogenous MeCP2 expression
in +/2 neurons, NSC were differentiated for 2 weeks. Since
MECP2 is an X-linked gene and undergoes X chromosome
inactivation in females, 50% of the +/2 neurons should express
MeCP2. Both Tubulin III+ neurons and GFAP+ glia expressing
MeCP2 were detected from the 1
st sphere (64.4%64.7 MeCP2+
cells) and 5
th sphere (48.2%65 MeCP2+ cells). Thus, the
percentage of MeCP2 expressing cells was initially higher in
primary spheres but adjusted to the expected 50% level after 5
passages. We speculate that MeCP2+ differentiated cells have a
growth advantage in vivo that is evident in the primary neuro-
spheres but is lost upon extended in vitro neurosphere culture.
We next tested the differentiation ability of transduced NSC
with MECP2-E1 constructs. Differentiation of these cells for two
weeks resulted in Tubulin III+ neurons and GFAP+ glia showing
nuclear Myc-tag staining colocalized with MeCP2 (data not
shown). The signals were detectable from both the EF1a
ubiquitous and MeP regulated promoters (Figure 7C). Quantifi-
cation of MeCP2 or MeCP2-myc positive cells revealed that
MeCP2-E1 expression reaches 95–100% of differentiated
Mecp2
tm1.1Bird+/2 NSC (Figure 7D). These findings show that
virtually all neurons derived from Mecp2
tm1.1Bird+/2 NSC express
transduced MECP2. Such efficient NSC gene transfer and
restricted expression pattern would be attractive for gene therapy
of RTT.
Transduced MeCP2-E1 promotes neuronal dendrite
branching
In neurons, MeCP2 is known to regulate glutamatergic
synapse formation [34], neuronal maturation and dendrite
arborization [32]. In order to test whether MeCP2-E1 overex-
pression directed from our retroviral vectors affects dendrite
formation of differentiated neurons, we differentiated transduced
NSC from the Mecp2
tm1.1Bird+/2 mice. Although two weeks of
differentiation resulted in Tubulin III+ neurons, a longer
differentiation period was required to detect dendrite branching.
NSC differentiated for three weeks and six weeks were stained for
the Tubulin III neuronal marker and MeCP2. By three weeks,
differentiated neurons with primary and occasionally secondary
dendrites were observed in the Retro-EF1a-E1 infected cells. In
contrast, control non-infected neurons did not show any
secondary dendrites and the length of their primary dendrites
appeared smaller (Figure 8A, top). At this time, neuronal
networks began to form in cells infected with the Retro-EF1a-
E1 but not in non-infected cells (Figure 8A, middle). Further
differentiation to six weeks promoted an increase in primary,
secondary and tertiary dendrite numbers in the infected cells,
while the non-infected cells did not develop secondary or tertiary
dendrites (Figure 8A, bottom).
To quantify neuronal maturation after Retro-EF1a-E1 infection
of +/2 NSC, images of distinct well-separated neurons were
analyzed using NeuronJ software. These measurements indicate
that non-infected axon length is not significantly smaller than
infected cells, but significant differences were observed for
increased primary, secondary and tertiary dendrite lengths in the
infected cells (Figure 8B). In terms of dendrite numbers, we also
detected significant differences in general branching and forma-
tion of dendrites (Figure 8C). In general, our data support previous
reports that MeCP2 is involved in neuronal maturation and
dendrite formation. We conclude that the transduced MeCP2 has
functional activity on the morphological maturation of neurons
in vitro.
Lentiviral vector delivery and long-term expression in
neurons
Transduced NSC could migrate after delivery into the brain
and produce neurons expressing MeCP2, but an attractive
alternative strategy for RTT gene therapy via MECP2 gene
transfer is to develop lentiviral vectors that infect pre-existing
neurons. We generated SIN lentiviral vectors containing the
500 bp dimer cHS4 core insulator in the LTRs [35]. MECP2-E1
or -E2 isoforms and an EGFP control were subcloned under the
control of either the EF1a or MeP promoters (Figure S3A). These
vectors were tested by infection of embryonic NSC, resulting in
long-term expression of MeCP2 only from the EF1a promoter
detected as punctate nuclear staining similar to that described with
the MECP2 retroviral vectors by IF (Figure S3B) and by WB
(Figure S4). Upon differentiation of infected NSC, MeCP2-myc-
positive neurons and glia were observed from both the EF1a and
MeP promoters (Figure S5). The data presented here show that
our lentiviral constructs express MeCP2 long-term in transduced
neurospheres and after neuronal differentiation.
We next tested the ability of the lentiviral vectors to transduce
differentiated neurons directly. In brain slice cultures, Lenti EF1a-
EGFP (Figure 9A) infected morphologically differentiated cells
with high efficiency and EGFP signals were maintained for 3
weeks (Figure 9B). Next, neurons were isolated from the brain
cortex of E18 mouse embryos and cultured up to 72 hours prior to
infection. These cells express endogenous MeCP2 as expected
(Figure 9C). They were infected with concentrated lentiviral
vectors and assayed for EGFP expression after 72 h. Flow
cytometry revealed that .80% and .70% of cells infected with
Lenti-EF1a-EGFP and Lenti-MeP-EGFP, respectively express
EGFP (Figure 9D) as confirmed by IF (Figure 9E). Finally,
Lenti-EF1a-E1 and MeP-E1 delivery (Figure 10A) also resulted in
MECP2 Gene Therapy Vectors
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colocalized with DAPI (Figure 10B). Overall, our lentiviral vectors
direct long-term MECP2 isoform expression in undifferentiated
NSC and/or their progeny neurons and glia, directly infect
dissociated neurons with high efficiency, and therefore are well
suited for future applications in RTT gene therapy.
Figure 5. Long-term EGFP expression in NSCs from Mecp2
tm1.1Bird+/2 female mice. NSCs from adult Mecp2
tm1.1Bird+/2 female mice were
infected with Retro-EF1a-EGFP (green), Retro-MeP-EGFP (blue), or non-infected control (red) and maintained in culture for 10 neurosphere
passages (1 passage per week). Flow cytometry analysis (left) shows maintained expression from Retro-EF1-EGFP (green line) but no significant
expression from Retro-MeP-EGFP (blue line). Live cell images (right) show EGFP expression in NSCs infected with Retro-EF1a-EGFP at indicated
passages.
doi:10.1371/journal.pone.0006810.g005
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tm1.1Bird+/2 female mice. NSCs were isolated from Mecp2
tm1.1Bird+/2
female brain and infected with Retro-EF1a-EGFP retroviral vector. EGFP expressing NSCs were injected into ex vivo slice cultures of Mecp2
tm1.1Bird+/2
female brain, and the EGFP positive NSCs that migrated were detected up to three weeks after NSC injection.
doi:10.1371/journal.pone.0006810.g006
Figure 7. Rescue of MeCP2 expression in differentiated adult NSCs from Mecp2
tm1.1Bird+/2 mice. A) MeCP2-E1 protein from EF1a
promoter was detected in whole-cell lysates of NSCs from Mecp2
tm1.1Bird+/2 female mice by WB using anti Myc-tag antibody. B) Undifferentiated
NSCs from Mecp2
tm1.1Bird+/2 female mice express Myc-tagged MeCP2-E1 from EF1a promoter, but not from MeP promoter. C) Differentiated NSCs
(for 14 days) from Mecp2
tm1.1Bird+/2 female mice show mosaic expression of endogenous MeCP2 (Non-infected). Myc-tagged MeCP2-E1 expression
was detected from both EF1a promoter (Retro-EF1a-E1) and MeP promoter (Retro-MeP-E1). D) Percentage of MeCP2 positive cells shows
approximately 50% of the cells expressing endogenous MeCP2 (Non-infected), whereas expression of MeCP2 protein in NSCs transduced by either
Retro-EF1a-E1 or Retro-MeP-E1 shows 90–100%. Error bars represent SEM (standard error of the mean). Scale bars represent 50 mm.
doi:10.1371/journal.pone.0006810.g007
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Long-term expression of EF1a-MECP2 vectors in adult
and embryonic NSC
Gene therapy seeks to obtain stable and long-term expression of
the engineered gene in transduced cells and their progeny. Stem
cells are commonly used because of their ability to differentiate
and generate a broad range of different cell types. However, one
obstacle in stem cell applications for gene therapy is silencing of
transduced genes. We generated SIN retroviral vectors using the
HSC1 backbone to avoid all known silencer elements, and
expressed EGFP and MECP2 isoforms under the control of the
strong ubiquitous EF1a promoter. We transduced NSC with high
efficiency of about 80% for MECP2 isoforms and showed long-
term expression over a period of 10 passages without evidence for
silencing of these advanced vector designs in NSC. Through ex vivo
NSC injection, continuous expression of the transduced genes in
the brain microenvironment of WT and Mecp2
tm1.1Bird+/2 female
mice was monitored and observed for 3 weeks. Moreover, NSC
from adult Mecp2
tm1.1Bird+/2 female mice maintained a stable
frequency of expressing cells from the first to the 10
th sphere. Our
data supports the finding that NSC from these mice have similar
sphere forming capacity as WT adult NSC [32], and the infection
efficiency of retroviral vectors are comparable. Overall, we show
stable and highly efficient retroviral transduction of NSC.
Restricted MeP-MECP2 expression in neurons and glia
For gene therapy of human disorders, regulated expression of
the transferred gene is generally preferred. MECP2 expression is
under tight developmental regulation, which is required for proper
postnatal brain development. In mice, Mecp2 overexpression in
post-mitotic neurons leads to profound motor dysfunction [29]
and mild 2-fold overexpression is accompanied by progressive
neurological disorders and premature death [36]. However,
transgene expression in the mutant background rescues the
phenotype [29]. It is therefore important to employ the
endogenous Mecp2 promoter in any RTT gene therapy attempt.
In our initial studies, we used the EF1a promoter and showed
highly efficient NSC transduction with our retroviral vectors.
Importantly, MeCP2 expression was directed to the correct
subnuclear localization at heterochromatic regions of the nucleus.
Overexpression of MECP2 did not overtly interfere with the
renewal capacity of NSC and these expressing cells were passaged
up to the 10
th spheres with no difficulty. We then demonstrated
endogenous MeCP2 expression in differentiated neurons and to a
lower level in GFAP+ cells derived in vitro and in vivo as recently
reported [19]. To mimic this endogenous expression pattern, we
created novel MECP2 isoform-specific vectors regulated by the
endogenous MeP promoter that directed MeCP2 expression in
neurons [30] and also glia [33]. Thus the MeP promoter vector
recapitulates the endogenous expression pattern and is well suited
Figure 8. MeCP2 overexpression promotes dendrite length and branching. A) NSCs from Mecp2
tm1.1Bird+/2 mice (15
th passage for non-
infected cells and 14
th passage for Retro-EF1a-E1 infected cells) were differentiated for 3 (top and middle panels) or 6 weeks (bottom panel), and
stained for MeCP2 (green) and neuronal marker Tubulin III (red) for dendrite maturation analysis. Scale bars represent 50 mm. B–C) Quantification of
axon and dendrite length (B) and dendrite numbers (C) shows that overexpression of MeCP2-E1 promoted dendrite formations. Error bars represent
SEM. * indicate P,0.05, ** indicate P,0.005.
doi:10.1371/journal.pone.0006810.g008
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PLoS ONE | www.plosone.org 9 August 2009 | Volume 4 | Issue 8 | e6810Figure 9. Efficient transduction of cortical neurons by lentiviral vectors expressing EGFP. A) Schematic of lentiviral vectors expressing
EGFP under the control of EF1a or MeP promoter. RRE: Rev-Responsive Element, cHS4: chicken b–globin locus Hypersensitive Site 4, cPPT: central Poly
Purine Tract, CTS: Central Terminal Sequence. B) Lenti-EF1a-EGFP vector was infected into the ex vivo brain slice from a wild-type mouse, and the
EGFP expressing cells were detected by live imaging for up to 3 weeks after infection. C) Endogenous MeCP2 expression (green) in nuclei of cortical
neurons (Tubulin III positive). D) Cortical neurons were infected in vitro with the lentiviral vectors expressing EGFP under the control of EF1a promoter
(left) or MeP promoter (right). Percentage of EGFP positive cells (green line) were assessed by flow cytometry. E) Both EF1a (left) and MeP (right)
promoter expressed EGFP in Tubulin III positive cortical neurons after infection of lentiviral vector. Scale bars represent 50 mm.
doi:10.1371/journal.pone.0006810.g009
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MeCP2 are expressed from the viral vectors, it will be important to
compare protein levels of endogenous and exogenous MeCP2 by
performing additional experiments. These may require MECP2
transgenes with a larger tag to distinguish the exogenous isoforms
from endogenous MeCP2 by protein size.
MeCP2-E1 expression in +/2 NSC and function in
neuronal maturation
As a model for gene therapy, we differentiated NSC from
Mecp2
tm1.1Bird+/2 female mice at the 5
th sphere passage and
observed endogenous MeCP2 expression in roughly 50% of the
cells as expected. However, when +/2 NSC were infected with
the Retro-EF1a-E1 and Retro-MeP-E1 vectors and differentiated,
between 95–100% of the cells were MeCP2-positive. These data
show that retrovirus vectors expressing from the EF1a ubiquitous
or MeP restricted promoters can convert virtually all +/2 NSC
into MeCP2+ cells.
To examine the function of the MeCP2-E1 isoform, Retro-
EF1a-E1 infected +/2 NSC were differentiated into neurons and
morphological features of neuronal maturation determined.
Significant increases in the length of primary dendrites, and
increased numbers of secondary and tertiary dendrites were
observed. These data are in agreement with the report that Mecp2-
null neurons have fewer dendrites and impaired synaptic
formation [37] and that Mecp2-null GFAP+ astrocytes stunt
dendrites in cocultured neurons [19]. The Mecp2-E1 isoform is the
dominant transcript detected in the mouse brain, and therefore its
role in dendrite formation and maturation in neurons, or its
supporting role in astrocytes, can now be examined in vivo using
our isoform-specific retrovirus vectors.
Lentiviral MECP2 delivery directly into neurons
In order to deliver MeCP2 isoforms directly into affected
neurons, we employed a safety-enhanced SIN lentiviral vector that
includes a dimer cHS4 core insulator element to prevent potential
insertional activation events. These lentiviral vectors express
EGFP and MECP2 isoforms from the EF1a and MeP promoters
in NSC, neurons and glia. As expected, MeCP2 was localized to
heterochromatic regions of the nucleus. Importantly, the lentivirus
vectors infected dissociated cortical neurons with high efficiency of
80% as well as brain slice cultures. Overall, our MeP lentiviral
vectors restrict MeCP2 expression to the neuronal lineage, and
prevent ectopic expression from occurring in NSC through their
ability to directly transduce affected neurons and glia. One
complication of direct lentivirus delivery is that X chromosome
inactivation in female patients leads to half the cells expressing
wild-type protein and half expressing mutant protein. Lentivirus
transduction will express the human isoform in all infected cells.
To address this issue, exogenous MECP2 expression could be
coupled to specific knockdown of the endogenous MeCP2 to
preserve total expression levels in heterozygous patient cells [38].
Routes for RTT gene therapy
We propose that MECP2 gene transfer for RTT gene therapy
can employ two routes. First, MeP retrovirus vectors can modify
NSC that subsequently differentiate into cells that express MeCP2
in the endogenous pattern. This approach is dependent on having
Figure 10. Efficient transduction of cortical neurons by lentiviral vectors expressing MeCP2 isoform. A) Schematic of lentiviral vectors
expressing human MeCP2 isoform (E1) with Myc-tag under the control of EF1a or MeP promoter. B) Expression of Myc-tagged MeCP2-E1 colocalized with
DAPI-richregions in the nuclei ofcortical neurons after infection with EF1a (top) and MeP (bottom) promoter lentiviral vectors. Scale bars represent 50 mm.
doi:10.1371/journal.pone.0006810.g010
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deriving induced pluripotent stem (iPS) cells from human
fibroblasts [39–41] now permit generation of patient-specific iPS
cells [42–44]. In fact, we recently reported the generation of RTT-
model mouse derived iPS cells and RTT-patient derived iPS cells
[44]. Conceivably, these cells could be used to model RTT disease
and as recipients for transduction with the MeP retrovirus or
insulated lentivirus vectors. Differentiation of genetically corrected
patient-specific iPS cells [45] might ultimately produce NSC
grown as neurospheres that could be dissociated for transplanta-
tion to generate both neurons and their supportive glial cells.
Second, the MeP lentivirus vectors can deliver the restricted
MECP2 transgene directly into neurons and glia. This approach
could be applied in vivo by direct virus injection into the chosen
regions of the brain depending on the severity of the symptoms of
each patient [46,47]. Alternatively, the MeP promoter constructs
could be delivered more broadly across the Blood Brain Barrier
through the use of Adeno-Associated Virus 9 derived vectors [48].
The feasibility of these approaches will need to be tested in mouse
models in vivo.
In summary, we generated MECP2 isoform-specific vectors and
demonstrate their long-term expression in transduced embryonic
and adult murine NSC. These viruses are not subject to stem cell-
specific viral silencing due to the advanced vector design and
maintain the expression of the transduced genes after neuronal
differentiation. Our MeP vectors recapitulate endogenous MeCP2
expression in neurons and glia and rescue mosaic MeCP2
expression in Mecp2
tm1.1Bird+/2 neurons. We clearly demonstrate
a functional role for MeCP2-E1 in regulating dendrite length and
branching during morphological maturation of Mecp2
tm1.1Bird+/2
neurons in vitro. Our advanced lentiviral EF1a vectors efficiently
transduce MECP2 into cortical neurons and direct it to the proper
nuclear compartments. These vectors are invaluable tools
facilitating functional studies of MeCP2 isoforms and have
important applications for RTT gene therapy.
Materials and Methods
Vector construction
pcDNA3.1A-MECP2A(E2)-myc and pcDNA3.1A-MECP2B(E1)-
myc vectors containing human MECP2-isoform cDNAs with Myc-
tag were kind gifts from Berge Minassian (Hospital for Sick
Children). We subcloned MECP2 isoforms into the HSC1-EF1a-
EGFP retrovirus vector [49]. The DNA was transformed into
SCS110 competent cells (Stratagene) to allow digestion with the
dam-methylation sensitive enzyme ClaI, blunted with T4 DNA
polymerase (Invitrogen) and digested with NcoI. The vector
backbone was 59 dephosphorylated using CIAP (Invitrogen) and
blunt ligated to 1.5 kb MeCP2-E2 released from pcDNA3.1A-
MECP2A(E2)-myc digested withPmeI and NcoI.Diagnostic digestion
with NcoI and SacI identified Retro-EF1a-E2 (same as HSC1-EF1a-
MECP2E2-myc) was further confirmed with SmaIa n dHindIII.
Retro-EF1a-E1 (same as HSC1-EF1a-MECP2E1-myc) was gener-
ated by PCR amplification of MECP2E1-myc from pcDNA3.1A-
MECP2B(E1)-myc to introduce NcoI( 5 9)a n dClaI( 3 9) sites to allow
direct sub-cloning into the HSC1-EF1a vector [forward primer: 59-
GAGCTCGGATCCGGACCATGGC-39 (NcoI site underlined);
reverse primer 59-CGATCGATAACTCAATGGTGATG-39 (ClaI
site underlined)]. The PCR product was cloned into TOPO 4.0 TA
(Invitrogen) and confirmed by automated sequencing. It was
digested by NcoIa n dClaI, and cloned into Retro-EF1a-EGFP
(same as HSC1-EF1a-EGFP) digested with NcoIa n dClaI (to release
the EGFP gene). Digestion with NcoIa n dSacI identified the clone
and confirmed by SmaIa n dHindIII digestion.
The MeP promoter was generated by PCR using genomic DNA
from J1 ES. The forward primer had an XbaI site followed by the
2678 to 2656 of the MeP promoter: 59-AGTCAGTCTA-
GATCTCTTATGGGCTTGGCACAC-39. Reverse primer includ-
ed an NcoI site positioned over the ATG start codon (E1 and E2 use
t h es a m eA T Gs t a r tc o d o n )e x t e n d i n gt o+27: 59-AGTCAGC-
CATGGTTTCCGGACGGGTTTTACC-39. The PCR product
contains an XbaI site followed by 2678 bp to an NcoIs i t eo v e rt h e
ATG start codon of the MeP-Mecp2 region. The PCR product was
cloned into pGEM-T-easy Vector (Promega). It was subsequently
double digested using the EcoRI site of the pGEM-T-easy vector and
the NcoI site introduced by PCR. The MeP promoter fragment was
gel purified with Qiagen Gel Extraction Kit. This resulted in the
introduction of an EcoRI, SpeIa n dXbaIs i t e5 9 to the MeP promoter
sequence. Nextour Retro-EF1a-E1andRetro-EF1a-E1vectorswere
digested with NcoIa n dEcoRI and gel purified. The EcoRI-SpeI-XbaI-
(2678)-Mep-(ATG)-NcoIf r a g m e n te n c o d i n gt h eM e Pp r o m o t e rw a s
ligated with the PL-cHS4 lentivirus vector backbone described
previously [35]. The lenti-MeP-EGFP construct was obtained by
ligating the 700 bp MeP fragment (Retro-MeP-EGFP; NcoI, BglII)
and the 1.6 kb EGFP fragment (Lenti-EF1a-EGFP; EcoRI, NcoI) into
the 5.2 kb Lentivirus backbone (Lenti-EF1a-EGFP; EcoRI, BamHI).
Lenti-EF1a-E1 and Lenti-EF1a-E2 constructs were obtained by
ligating the 1.8 kb MECP2E1 and 1.8 kb MeCP2E2 fragments
respectively (Retro-EF1a-E1 and Retro-EF1a-E2; NdeIt r e a t e dw i t h
Klenow and subsequently XhoI) into the 7.1 kb lentivirus backbone
(Lenti-EF1a-EGFP (NruI, XhoI). Lenti-MeP-E1 and Lenti-MeP-E2
constructs were obtained by ligating the 700 bp MeP fragment
(Retro-MeP-EGFP; NcoI, BglII) and the 2.4 kb MeCP2E1 and 2.4 kb
MeCP2E2 fragments respectively (Lenti-EF1a-E1 and Lenti-EF1a-
E2; EcoRI, NcoI) into the 5.2 kb lentivirus backbone (Lenti-EF1a-
EGFP; EcoRI, BamHI).
NSC isolation, culture and differentiation
Mouse embryonic NSC were isolated from the forebrain of
E14.5 embryos. Dissected tissues were collected by brief
centrifugation, homogenized through a flame narrowed pasteur
pipette, filtered through a 40 mm filter and plated at 10
5 cells/cm
2
in NSC media DMEM/F12 1:1 (Wisent Inc.) in the presence of
rhEGF (Sigma, 20 ng/ml), bFGF (Upstate, 20 ng/ml), Heparin
(Sigma, 2 mg/ml) and hormone mix [50]. The neurospheres were
dissociated to single cells every 7 days for sub cultures with
Accutase treatment (Sigma; 1 ml, 2–5 min at 37uC), washed with
basic media, filtered and cultured in 50:50 fresh media and
conditioned media (old NSC media). For differentiation, single
cells were cultured in the presence of 10% FBS (Fetal Bovine
Serum, Invitrogen) with no rhEGF or bFGF and grown on growth
factor reduced Matrigel (BD) and the media was changed every
other day. For adult mouse NSC, we dissected the Subventricular
Zone (SVZ) of the forebrain into small pieces, collected by brief
centrifugation, resuspended into 50 ml digestion mix [Hi/Low
ACSF plus Trypsin (Sigma), 1.33 mg/ml; Hyaloronidase (Sigma),
0.67 mg/ml; Kynurenic acid (Sigma), 0.1–0.17 mg/ml] at 37uC
(30 minutes). Tissue was collected by centrifugation and resus-
pended in 10 ml antitrypsin (Ovalbumin 0.7 mg/ml, Sigma),
centrifuged and resuspended in 2 ml of full NSC media. The tissue
was homogenized with a flame narrowed pasteur pipette about 40
times and plated at low density. Subculturing and differentiation
was similar to the embryonic NSC.
Retroviral production and NSC transduction
Retroviruses were prepared in Phoenix ecotropic packaging
cells cultured in Dulbecco’s modified Eagle’s medium (DMEM,
Invitrogen) with 10% FBS using Lipofectamine 2000 (Invitrogen)
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with NSC media and the virus was harvested 24 h later for NSC
infection. Dissociated NSC were filtered, counted and were
infected overnight with freshly made virus (1:1 virus: media fresh
media) in the presence of 6 mg/ml Polyberene (Sigma). The virus
was removed the next day and the cells were plated in fresh media.
Lentiviral production
Lentivirus vectors were produced in 293-T cells cultured in
DMEM with 10% FBS. For lentiviral production, 293-T cells were
plated at a density of 8610
6 in T-75 flasks. The following day, the
cells were transfected using Lipofectamine 2000 (Invitrogen) with
10 mg HPV275 (gag/pol expression plasmid), 10 mg P633 (rev
expression plasmid), 10 mg HPV17 (tat expression plasmid), 5 mg
pHCMV-VSV-G (VSV-G expression plasmid) and 15 mg of PL-
cHS4 based MECP2 lentivirus vectors. The lentiviruses were
collected in 20 ml media after 481h, filtered through 0.45 mm
pore filters and concentrated by ultracentrifugation at 4uC, 2 h,
30,000 rpm with T-865 rotor (Sorvall). The pellet was resus-
pended to final volume of 80 ml with Hanks’ balanced salt solution
(HBSS, Invitrogen) overnight at 4uC. Next day, 10
5 target cells
were infected with lentiviruses at different doses (4, 10 or 40 ml) in
the presence of 8 mg/ml polybrene. After 24 h, the media was
replaced with fresh medium. Virus titers were estimated by flow
cytometry using the formula: N6M / 100 V; N is the number of
target cells used for infection, M is % expressing cells, and V is the
volume of concentrated virus used (ml).
Brain slice culture
The brain of WT or Mecp2
tm1.1Bird+/2 female mice (The
Jackson Laboratory) were dissected in HBSS and sliced with a
tissue chopper (McIlwain, Campdan Instruments, Lafayette, IN)
into coronal sections of about 300 mm [51] prior to infection with
lentiviruses or injection with transduced NSC. Intact slices were
selected and transferred onto a millicell sterilized 0.4 mm culture
plate insert (Millipore), then placed into a six-well culture plate
containing 700 ml of media, composed of basal medium Eagle’s
(Invitrogen), with 25% vol/vol Hank’s Balanced salt solution
(Invitrogen), 25% vol/vol heat inactivated horse serum (Invitro-
gen), 0.2% wt/vol glucose (culture grade, Sigma) and 0.65% wt/
vol sodium bicarbonate (culture grade, Sigma). Approximately 5
brain sections were placed per insert, and media was changed
every 3 days. Injections were done under a dissection microscope
using a Hamilton syringe and pulled capillary tubes. For NSC
injections, 1 ml of dissociated neurospheres with a concentration of
100,000 cells/ml was injected into the subventricular zone. For
lentiviral infection, 20 ml of concentrated virus was added to the
media and 20 ml of the virus was added to the top of the brain slice
as a drop in the presence of 1 mg/ml polybrene overnight, with
media changed the next day.
Neuronal dissociation and infection
Postmitotic cortical neurons were isolated from E18 mouse
embryos [52] and cultured on cover-slips in Neurobasal media
(Invitrogen) supplemented with B27 (Invitrogen). After 3 days the
cells were infected with 1 ml of concentrated lentiviruses (with
0.6 mg/ml polybrene). The virus was removed after 5–7 h and the
cells were incubated with fresh media. After 48 h the cells were
fixed and processed for IF.
Neuronal tracing
We used ImageJ software (http://rsb.info.nih.gov/ij/) with
NeuronJ plugin software (http://www.imagescience.org/meijering/
software/neuronj/) for neuronal tracing and measurements. We
quantified the axonal and dendrite length of 6 neurons in control
and 11 neurons in infected cells, due to the small number of isolated
cells that we could trace. P values for all the quantifications were
measured and are presented as * P,0.05 and ** P,0.005.
Immunostaining
Dissociated cells were plated on cover-slips coated with growth
factor reduced Matrigel for undifferentiated/differentiated NSC or
Poly-L-lysine (Sigma) for cortical neurons. Cells were washed twice
with Phosphate Buffered Saline (PBS, Invitrogen) and fixed in
100% methanol at 220uC for 30 min. Cover slips were air dried
and kept at 220uC until stained. For staining they were
rehydrated in PBS (5 minutes), blocked 1 h at room temperature
(RT) with 10% normal goat serum (NGS) in PBS and incubated
with the primary antibody in 10% NGS, 1 h RT. They were then
washed three times with PBS (5 minutes), incubated with the
secondary antibody in 10% NGS for 1 h at RT, washed three
times with PBS and mounted in antifade and DAPI (0.5 mg/ml).
Antibodies
The following antibodies were used: anti-C-Myc, (Rabbit, SC789
Santa Cruz, IF 1:200; WB 1:500); anti-C-Myc (Mouse, A21280
Molecular Probes, IF 1:200; WB 1:500); anti-GFAP (Mouse,
A21282 Molecular Probes, IF 1:200); anti-MeCP2 (Rabbit, 07-
013 Upstate, IF 1:200); anti-Tubulin bIII (Mouse, MAB1637
Chemicon, IF 1:200); anti-GFP Alexafluor-488 (A21311 Molecular
Probes, IF 1:400); anti-Actin (Mouse, Sigma, AC15).
Total cell extracts and Western Blot (WB)
Total cell extracts were prepared as described previously [53]
and WB was done with 20 mg of total cell extracts as described
elsewhere [53].
Flow cytometry. Flow cytometry was performed using a
FACScan (Becton–Dickinson) in the Hospital for Sick Children
Flow Cytometry Facility and analyzed with FlowJo software.
Supporting Information
Figure S1 NSC migration into the brain microenvironment in ex
vivo culture. EGFP expressing NSCs (infected with Retro-EF1a -
EGFP) were injected into brain slices of wild-type mouse, and
EGFP expressing cells were detected by live imaging at the
indicated days after injection.
Found at: doi:10.1371/journal.pone.0006810.s001 (1.46 MB EPS)
Figure S2 Generation and maintenance of NSCs from
Mecp2
tm1.1Bird+/2 female mice. A) Mecp2
tm1.1Bird+/2 female mouse
displayed RTT symptoms such as hind limb clasping and small
brain (inset, scale bar 5 mm). B) Neurospheres were generated
from Mecp2
tm1.1Bird+/2 female brain. NSCs were maintained up to
21 passages for non-infected control (left), and 20 passages for
Retro-EF1a-E1 infected control (right).
Found at: doi:10.1371/journal.pone.0006810.s002 (1.69 MB EPS)
Figure S3 MeCP2 delivery into NSC by lentiviral vectors. A)
Schematic of lentiviral vectors expressing human MeCP2 isoforms
(E1 or E2) with Myc-tag under the control of EF1a or MeP
promoter. B) Dissociated NSCs were infected with indicated
lentiviral vector expressing MeCP2 isoforms. Immunofluoresence
staining shows colocalization of Myc-tag and MeCP2 signals in
DAPI-richregionfromthe EF1a promoter.Notransgene expression
(Myc-tag) was detected from the MeP promoter in NSCs, as with
endogenous mouse MeCP2. Scale bars represent 50 mm.
Found at: doi:10.1371/journal.pone.0006810.s003 (4.42 MB EPS)
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lentiviral vector infection. NSCs were infected with indicated
lentiviral vectors and whole-cell lysates were extracted from 1st
sphere (1st Sph.) and 5th sphere (5th Sph.). Expression of MeCP2
isoforms was detected by WB using anti Myc-tag antibody from
the EF1a promoter, but not from the MeP promoter.
Found at: doi:10.1371/journal.pone.0006810.s004 (1.02 MB EPS)
Figure S5 MeP promoter is active in neurons and glia after
differentiation of NSCs. Infected NSCs with indicated lentiviral
vector were differentiated for 14 days. Immunofluorescense images
show nuclear localization of exogenous MeCP2 protein (Myc-
tagged) in Tubulin III positive neurons and GFAP positive glia.
Scale bars represent 50 mm.
Found at: doi:10.1371/journal.pone.0006810.s005 (2.21 MB EPS)
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